Outcome of Patients With Primary Aldosteronism

  • STATUS
    Recruiting
  • days left to enroll
    31
  • participants needed
    600
  • sponsor
    Changi General Hospital
Updated on 22 August 2021
hypertension
aldosterone
adrenalectomy
cardiovascular morbidity
essential hypertension
hyperaldosteronism

Summary

Majority of patients with hypertension have primary hypertension (without an underlying cause). Primary aldosteronism (PA) is the most common cause of secondary hypertension, and can be found in 5-10% of patients locally. PA is caused by excessive release of a hormone (aldosterone) from the adrenal glands, which can be unilateral (one gland) or bilateral (both glands).

It has been shown that excess aldosterone has other harmful effects in addition to hypertension, such as directly affecting the heart, blood vessels, kidneys, leading to increased cardiovascular morbidity and mortality. This is supported by studies showing reversal of these effects after treatment for PA.

The investigators aim to assess the long-term cardiovascular, and renal outcomes of patients with PA, compared to patients with essential hypertension.

Details
Condition end stage renal failure, end-stage renal failure, Adrenalectomy; Status, Hyperaldosteronism, Kidney Failure, chronic kidney disease, end-stage renal disease, Mineralocorticoid Excess, Mineralocorticoid Antagonists [Aldosterone Antagonists] Causing Adverse Effects in Therapeutic Use, end stage kidney disease, Hypokalemia, Chronic renal failure, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral), Primary Aldosteronism Due to Aldosterone Producing Adenoma, chronic kidney disease (ckd), conn, chronic renal insufficiency, end stage renal disease, primary hyperaldosteronism, chronic renal disease, Kidney Failure (Pediatric), esrd, Renal Failure, Cardiovascular Morbidity, primary aldosteronism
Treatment Unilateral adrenalectomy in patients with unilateral disease
Clinical Study IdentifierNCT04428827
SponsorChangi General Hospital
Last Modified on22 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with suspected primary aldosteronism

Exclusion Criteria

Nil
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note